UBQLN3 Inhibitors
UBQLN3 inhibitors are not a class of compounds that target UBQLN3 directly; instead, these molecules exert their effects by modulating the ubiquitin-proteasome system (UPS), a cellular pathway critical for protein turnover and homeostasis to which UBQLN3 is closely tied. UBQLN3 has a role in shuttling polyubiquitinated proteins to the proteasome, where they are degraded. Proteasome inhibitors such as MG132 and Carfilzomib lead to an increase in the cellular concentration of polyubiquitinated proteins. This accumulation can potentially inhibit UBQLN3 by overwhelming its ability to interact with and transport these proteins to the proteasome. The excess of substrates competing for UBQLN3's attention can impair its shuttle function, leading to a decrease in the degradation of ubiquitinated proteins, thus indirectly inhibiting UBQLN3's activity
The indirect inhibition of UBQLN3 through the use of proteasome inhibitors is a consequence of disrupting normal proteostasis, which is the balance of protein synthesis, folding, and degradation within the cell. By impeding the proteasome's ability to degrade ubiquitinated proteins, these inhibitors cause an accumulation of these proteins within the cell. This accumulation can sequester UBQLN3, as it becomes engaged with an excessive number of ubiquitinated proteins, exceeding its capacity to shuttle these proteins effectively to the proteasome.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Since UBQLN3 is involved in the recognition and sorting of polyubiquitinated proteins to the proteasome, inhibition of the proteasome by MG132 can lead to the accumulation of polyubiquitinated proteins, which may sequester UBQLN3 and impair its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor that, similar to MG132, can cause the accumulation of ubiquitinated proteins, potentially overloading UBQLN3's capacity to shuttle these proteins to the proteasome, thus indirectly reducing UBQLN3's functional activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasomal beta subunits. By blocking proteasomal activity, it would lead to a buildup of proteins destined for degradation, possibly occupying UBQLN3 and thereby inhibiting its normal function. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. By blocking the degradation pathway of ubiquitinated proteins, it can indirectly inhibit UBQLN3 by causing an overload of substrates that UBQLN3 cannot process efficiently. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is a proteasome inhibitor designed to be more potent and selective than Bortezomib. It would similarly affect UBQLN3 by increasing the number of ubiquitinated proteins, possibly disrupting UBQLN3-mediated pathways. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an orally bioavailable proteasome inhibitor. Its inhibition of the proteasome could lead to elevated levels of ubiquitinated proteins, thereby indirectly reducing the functional activity of UBQLN3. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a proteasome inhibitor that, by increasing ubiquitinated proteins, could saturate UBQLN3's ability to handle these proteins, leading to functional inhibition. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
ONX-0914 is an immunoproteasome inhibitor that specifically targets the LMP7 subunit. Its effect could lead to an increase in ubiquitinated proteins, which would indirectly inhibit UBQLN3 by overwhelming its regulatory capacity. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $150.00 $210.00 $1899.00 | 39 | |
Auranofin is a thioredoxin reductase inhibitor that also has been found to inhibit the proteasome. By inhibiting proteasomal activity, auranofin could increase ubiquitinated protein levels, potentially inhibiting UBQLN3. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A is a steroidal lactone that has been shown to inhibit proteasomal activity. This inhibition can lead to an accumulation of ubiquitinated proteins, which would indirectly inhibit UBQLN3. | ||||||